This study examined the relation between depression diagnoses and outcomes in 132 cocaine-dependent patients who were randomized to relapse prevention (RP) or standard 12-step focused group continuing care and followed for 2 years. Depressed patients attended more treatment sessions and had more cocaine-free urines during treatment than participants without depression, but they drank alcohol more frequently before treatment and during the 18-month posttreatment follow-up. Cocaine outcomes in depressed patients deteriorated to a greater degree after treatment than did cocaine outcomes in patients without depression, particularly in patients in RP who had a current depressive disorder at baseline. The best alcohol outcomes were obtained in nondepressed patients who received RP. The results suggest that extended continuing care treatment may be warranted for cocaine-dependent patients with co-occurring depressive disorders.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Potential use of quercetin in the reduction of craving in cocaine-dependent patients-A pilot clinical trial.
Phytother Res
March 2024
Laboratório de Produtos Naturais, Universidade São Francisco, São Paulo, Brazil.
Concomitant Drug Use among Opioid-Dependent Patients with and without Attention Deficit Hyperactivity Disorder: Does Methylphenidate Merit a Trial?
Eur Addict Res
October 2023
Psychiatric Services Lucerne, Lucerne, Switzerland.
Introduction: Concomitant drug use is common among opioid-dependent patients in maintenance therapy. Attention deficit hyperactivity disorder (ADHD), a common comorbidity among opioid users, is associated with a higher risk of concomitant drug use. Earlier studies showed that methylphenidate (MPH) can reduce cocaine consumption among patients with ADHD.
View Article and Find Full Text PDFSample size estimation for comparing dynamic treatment regimens in a SMART: A Monte Carlo-based approach and case study with longitudinal overdispersed count outcomes.
Stat Methods Med Res
July 2023
Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.
Dynamic treatment regimens (DTRs), also known as or , play an increasingly important role in many health domains. DTRs are motivated to address the unique and changing needs of individuals by delivering the type of treatment needed, when needed, while minimizing unnecessary treatment. Practically, a DTR is a sequence of decision rules that specify, for each of several points in time, how available information about the individual's status and progress should be used in practice to decide which treatment (e.
View Article and Find Full Text PDFTime Perception in Cocaine-Dependent Patients.
Brain Sci
June 2022
Novella Fronda Foundation, 35121 Padova, Italy.
Article Synopsis
- The dopamine system plays a key role in how we perceive time, with disruptions in this system affecting timing in conditions like Parkinson's disease and addictions.
- The study investigated whether chronic stimulant use impacts how individuals process time intervals by having participants complete tasks involving different stimulus durations.
- Both stimulant-dependent patients and control participants showed similar abilities to perceive time, but patients exhibited greater variability in their responses, suggesting issues with cognitive functions rather than time processing itself.
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.
Eur J Clin Pharmacol
June 2022
The Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 2002 Holcombe Blvd., Research 151, Building 110, Suite 227, Houston, TX, 77030, USA.
Purpose: The aim of this secondary analysis was to identify prodynorphin (PDYN) genetic markers moderating the therapeutic response to treatment of cocaine dependence with buprenorphine/naloxone (Suboxone®; BUP).
Methods: Cocaine-dependent participants (N = 302) were randomly assigned to a platform of injectable, extended-release naltrexone (XR-NTX) and one of three daily medication arms: 4 mg BUP (BUP4), 16 mg BUP (BUP16), or placebo (PLB) for 8 weeks (Parent Trial Registration: Protocol ID: NIDA-CTN-0048, Clinical Trials.gov ID: NCT01402492).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!